ADRB3 and overactive bladder: A new, highly selective beta-3 adrenoceptor agonist, vibegron, has recently been introduced for the treatment of patients with overactive bladder (OAB), and has demonstrated significant improvement in micturition, urgency and incontinence episodes [4], and its long-term safety and tolerance [5].